Amplification of HER2 can be found in 12% of EGFR TKI-resistant cell lines8 and two clinical studies detected HER2-amplification in 13% of NSCLC-patients with acquired EGFR TKI resistance.4,9. This evidence concerns the gene EGFR and non-small cell lung carcinoma.